877384-16-2

Usage

Uses

Used in Pharmaceutical Research:
Benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate is used as a key intermediate in pharmaceutical research for the development of novel therapeutic agents. Its unique structure and properties make it a valuable component in the synthesis of new drugs with potential applications in various medical fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate is employed as a building block for the design and synthesis of bioactive compounds. Its versatile structure allows for the creation of molecules with specific biological activities, making it a valuable tool for the discovery of new pharmaceuticals.
Used in Drug Design:
Benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate is utilized as a structural element in drug design, where its unique features can be exploited to create molecules with desired pharmacological properties. Its incorporation into drug candidates can enhance their efficacy, selectivity, and safety profiles, leading to the development of more effective treatments for various diseases.
Used in Chemical Synthesis:
In chemical synthesis, benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate serves as a versatile reagent and precursor for the preparation of a wide range of organic compounds. Its ability to participate in various chemical reactions makes it a valuable asset in the synthesis of complex molecules and advanced materials.
Used in Drug Development:
Benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate is employed as a crucial component in drug development, where its unique properties can be leveraged to create innovative therapeutic agents. Its incorporation into drug candidates can improve their pharmacokinetic and pharmacodynamic profiles, leading to the development of more effective and safer medications for patients.

Upstream product

• 871917-79-2 benzyl {(1S)-2-[3,5-bis(trifluoromethyl)phenyl]-1-methyl-2-oxoethyl}carbamate 
• 328-70-1 3,6-bis(trifluoromethyl)bromobenzene 
• 114744-83-1 (S)-benzyl (1-(N,O-dimethylhydroxylamine)-1-oxopropan-2-yl)carbamate 

Downstream Products

• 875444-08-9 (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one 
• 1220703-07-0 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)amino]propan-1-ol 
• 875446-37-0 anacetrapib 
• 1620289-77-1 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[(E)-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methylidene)amino]propan-1-ol 
• 1152029-16-7 (1R,2S)-2-amino-1-[3,5-bis(trifluoromethyl)phenyl]propan-1-ol 

Relevant academic research and scientific papers

Chiral purification method of drug intermediate

The invention provides a chiral purification method of a drug intermediate. The chiral purification method of the drug intermediate comprises the following steps: (1) adding a low-optical-purity compound as shown in a formula A4 into a solvent A, carrying

Method for preparing arene beta-amino alcohol of optical voidness

The invention discloses a method for preparing arene beta-amino alcohol of optical voidness. The method is characterized by comprising the following steps that a D or L-amino acid initial material reacts with benzyl chloroformate CBz-Cl or BOC acid anhydr

PROCESS FOR PREPARATION OF ANACETRAPIB AND INTERMEDIATES THEREOF

The present invention relates to a novel process for the preparation of anacetrapib. The present invention also relates to novel intermediate or its salt and its use in the preparation of anacetrapib.

NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone deriva

Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: Modifications of the oxazolidinone ring leading to the discovery of anacetrapib

The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically, it was found that substitution of the 4-position with a methyl group with the cis-stereochemistry relative to the 5-aryl group afforded compounds with increased cholesteryl ester transfer protein (CETP) inhibition potency and a robust in vivo effect on increasing HDL-C levels in transgenic mice expressing cynomolgus monkey CETP.

Highly diastereoselective catalytic Meerwein-Ponndorf-Verley reductions

Very practical synthesis of ephedrine analogues in high yields and enantiopurity was realized by a highly diastereoselective Meerwein-Ponndorf- Verley (MPV) reduction of protected α-amino aromatic ketones using catalytic aluminum isopropoxide. The high anti selectivity resulted from the chelation of the nitrogen anion to the aluminum. In contrast, high syn selectivity was obtained with α-alkoxy ketones and other compounds via Felkin-Ahn control.

CETP INHIBITORS

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalky substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalky substituent connected directly to the ring or attached to the ring through a -CH2-.